Monkeypox Vaccine And Treatment Market Size, Trends, Share, Growth | Report 2022-2030
Around the world, and especially in developed economies such as the U.S., Monkeypox is becoming a global threat. In July 2022, WHO declared monkeypox a public health emergency. According to the CDC, as of July 2022, around 7,102 infections have been reported in the U.S.
Research shows it is relatively more prevalent among the LGBTQ community and sexually active individuals with multiple partners. With the rising cases, the demand for monkeypox treatment is also increasing. However, there is a dearth of vaccine availability that would create lucrative opportunities for market players. According to CDC, across the U.S., only around 1.5 million to 1.6 million individuals are vaccinated so far, which makes up to about 600,000 doses of two-dose vaccine.
In North America and several European countries, two vaccines and antiviral drugs have been approved for monkeypox, previously used for smallpox treatment and eradication.
The U.S. government included the ACAM2000 drug in its strategic stockpile for the treatment of monkeypox. However, it is not commercially available yet. Currently, Siga Technologies’ Tecovirimat (TPOXX) and Chimerix’s brincidofovir (TEMBEXA) are two FDA-approved drugs for smallpox that are commonly recommended for the treatment of certain patients with monkeypox. According to CDC, past data from Africa suggests that the smallpox vaccine can be 855% effective in treating monkeypox
However, the companies reported a major shortage of drugs, which is projected to slow down the market growth in the initial forecast period. Such a robust demand is leading to intense competition amongst the players to develop new antivirals for the treatment of disease.
Among the product types, vaccine segment is anticipated to exhibit lucrative growth in the forthcoming years; this is more likely due to the high demand for vaccines in the market.
Players are robustly engaged in strategic initiatives, which is anticipated to fuel the monkeypox treatment market growth. For instance, in July 2022, Bavarian Nordic signed an agreement with the U.S. Department of Health and Human Services (HHS) for 2.5 million doses of Jynneos vaccine for the rapid availability of the vaccines in the U.S. Major companies operating in the space include Bavarian Nordic, EMERGENT, Siga Technologies, and Chimerix.
Market Segmentation
By Product type
By Regional Outlook
Chapter 1. Introduction
1.1.Research Objective
1.2.Scope of the Study
1.3.Definition
Chapter 2. Research Methodology
2.1.Research Approach
2.2.Data Sources
2.3.Assumptions & Limitations
Chapter 3. Executive Summary
3.1.Market Snapshot
Chapter 4. Market Variables and Scope
4.1.Introduction
4.2.Market Classification and Scope
4.3.Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5.COVID 19 Impact on Monkeypox Vaccine And Treatment Market
5.1. COVID-19 Landscape: Monkeypox Vaccine And Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4.Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1.Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2.Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1.List of Suppliers
7.1.3.2.List of Buyers
Chapter 8. Global Monkeypox Vaccine And Treatment Market, By Product type
8.1.Monkeypox Vaccine And Treatment Market, by Product type Type, 2020-2027
8.1.1. Vaccines
8.1.1.1.Market Revenue and Forecast (2016-2027)
8.1.2. Drugs
8.1.2.1.Market Revenue and Forecast (2016-2027)
Chapter 9. Global Monkeypox Vaccine And Treatment Market, Regional Estimates and Trend Forecast
9.1.North America
9.1.1. Market Revenue and Forecast, by Product type (2016-2027)
9.1.2. U.S.
9.1.3. Rest of North America
9.1.3.1.Market Revenue and Forecast, by Product type (2016-2027)
9.2.Europe
9.2.1. Market Revenue and Forecast, by Product type (2016-2027)
9.2.2. UK
9.2.2.1.Market Revenue and Forecast, by Product type (2016-2027)
9.2.3. France
9.2.3.1.Market Revenue and Forecast, by Product type (2016-2027)
9.2.4. Rest of Europe
9.2.4.1.Market Revenue and Forecast, by Product type (2016-2027)
Chapter 10.Company Profiles
10.1.Bavarian Nordic
10.1.1.Company Overview
10.1.2.Product Offerings
10.1.3.Financial Performance
10.1.4.Recent Initiatives
10.2.EMERGENT
10.2.1.Company Overview
10.2.2.Product Offerings
10.2.3.Financial Performance
10.2.4.Recent Initiatives
10.3.Siga Technologies
10.3.1.Company Overview
10.3.2.Product Offerings
10.3.3.Financial Performance
10.3.4.Recent Initiatives
10.4.Chimerix
10.4.1.Company Overview
10.4.2.Product Offerings
10.4.3.Financial Performance
10.4.4.Recent Initiatives
Chapter 11.Research Methodology
11.1.Primary Research
11.2.Secondary Research
11.3.Assumptions
Chapter 12.Appendix
12.1.About Us
12.2.Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers